Abstract
The synthesis of BILN 2061, an NS3 protease inhibitor with proven antiviral effect in humans, was accomplished in a convergent manner from four building blocks. The procedure described here was suitable for the preparation of multigram quantities of BILN 2061 for preclinical pharmacological evaluation.
Copyright 2004 American Chemical Society
MeSH terms
-
Antiviral Agents / chemical synthesis*
-
Antiviral Agents / chemistry
-
Antiviral Agents / pharmacology*
-
Carbamates / chemical synthesis*
-
Carbamates / chemistry
-
Carbamates / pharmacology*
-
Hepacivirus / drug effects
-
Hepacivirus / enzymology
-
Humans
-
Macrocyclic Compounds / chemical synthesis*
-
Macrocyclic Compounds / chemistry
-
Macrocyclic Compounds / pharmacology*
-
Molecular Structure
-
Protease Inhibitors / chemical synthesis*
-
Protease Inhibitors / chemistry
-
Protease Inhibitors / pharmacology*
-
Quinolines / chemical synthesis*
-
Quinolines / chemistry
-
Quinolines / pharmacology*
-
Thiazoles / chemical synthesis*
-
Thiazoles / chemistry
-
Thiazoles / pharmacology*
-
Viral Nonstructural Proteins / antagonists & inhibitors*
-
Viral Nonstructural Proteins / metabolism
Substances
-
Antiviral Agents
-
BILN 2061
-
Carbamates
-
Macrocyclic Compounds
-
NS3 protein, hepatitis C virus
-
Protease Inhibitors
-
Quinolines
-
Thiazoles
-
Viral Nonstructural Proteins